Reed Jobs would rather talk about curing cancer than his last name
Reed Jobs, the son of Steve Jobs, is focused on curing cancer through his oncology-focused venture firm Yosemite. He launched Yosemite in 2023 to build biotech companies from scratch using a mix of philanthropy and venture capital. Yosemite has made significant progress, with a team of 17 and a cluster of blockbuster drugs losing patent protection, creating new opportunities for the firm.
- ▪Reed Jobs launched Yosemite in 2023 to build biotech companies from scratch, focusing on oncology.
- ▪Yosemite uses a mix of no-strings-attached philanthropy and old-fashioned venture capital to fund its companies.
- ▪The firm has a team of 17 and is targeting $350 million for its second fund.
Opening excerpt (first ~120 words) tap to expand
Reed Jobs is easy to like. He’s motormouthed, self-deprecating, prone to video-game analogies, and clearly loves his work. He doesn’t particularly want to discuss the fact that he is Steve Jobs’s son, but he’s not uptight about it, either. When our producer, Maggie, asked if he was on a MacBook for our video call Thursday morning, he didn’t miss a beat: “Are you kidding?” What he’d much rather talk about is Yosemite, the oncology-focused venture firm he launched in 2023 to, in part, build biotech companies from scratch, out of early academic research, using a mix of no-strings-attached philanthropy and old-fashioned venture capital.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at TechCrunch.
Discussion
0 commentsMore from TechCrunch
